Ann: Mesoblast Phase 3 Chronic Heart Failure Results, page-314

Just listened to broadcast.

Largest trial ever re heart failure.

This helps point to where, who and when from a administrative if cells for optimal maximal treatment.

THIS IS A FANTASTIC RESULT.

Unexpectedly good for class 2 market in heart disease. Achieving this is HUGE.
Large Pharma will LOVE this.
Massive commercial opportunities. They have locked down the optimum time to intervene in chronic heart problems to be MOST effective. When the patient is most likely to respond successfully.
Paradigm of how heart failure will be considered in its treatment. Add on to other therapy so not a threat to big pharma.

Safe

(Imo only of course)